---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002861"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:37.757266+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook

## Summary
- Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.
- Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.
- Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).
- Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements.

## SEC filing metadata
- accession: 0001104659-26-002861
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/0001104659-26-002861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465926002861/tm262952d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002861
- JSON: https://secwatch.observer/filing/0001104659-26-002861.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.